Loading data for IMMX — first visit, this takes a few seconds.

アラート

Immix Biopharma Inc. (IMMX)

NasdaqCM: IMMX · リアルタイム株価 · USD

13.19

+1.38 (11.69%)

終値時点： Aug 19, 2026, 8:00 PM

13.20

+0.08%

時間外: 7:45 PM

11.69% (1D)

データがありません

買気配	9.36
時価総額	939M
売上高（TTM）	n/a
純利益（TTM）	-39.92M
ベータ	0.11
EPS（TTM）	-0.98
PER（TTM）	n/a
予想PER	-14.59
PBR（TTM）	4.12
PSR（TTM）	n/a
Earnings Date	n/a

売気配	15.36
出来高	1,958,312
平均出来高（20日）	1,912,380
始値	11.99
前日終値	11.81
当日レンジ	11.99 - 13.19
52週レンジ	1.94 - 13.19
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

IMMXについて

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Dec 16, 2021

従業員数 21

上場取引所 NasdaqCM

ティッカー IMMX

ウェブサイト https://www.immixbio.com

企業情報の全文

業績

2025年のImmix Biopharmaの売上高は0で、前年の0からundefined%の増加でした。利益は-29.44Mで、36.21%の増加でした。

財務諸表

決算サプライズ

Immix BiopharmaはAug 7, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.18 で、予想を下回りました 0.00, うち 18.18% の前年比増加にあたります.

ニュース

1か月前 · Investor's Business Daily

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

2か月前 · Zacks

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

2か月前 · Simply Wall St.

Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

2か月前 · Zacks

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3か月前 · Simply Wall St.

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

2ページ中1ページ

Immix Biopharma Inc. (IMMX)